| June, 2009 |
Phase II clinical study of CBP501 + Pemetrexed + Cisplatin in patients with Non-Small Cell Lung Cancer initiated in U.S. |
| June, 2009 |
Preclinical study of CBS9106 initiated. |
| November, 2008 |
Phase II clinical study of CBP501 + Pemetrexed + Cisplatin in patients with Malignant Pleural Mesothelioma initiated in U.S. |
| May, 2008 |
Phase I clinical study of CBP501 + Pemetrexed + Cisplatin has been initiated in U.S. |
| April, 2008 |
Patent application for low molecular compound CBS9100 series |
| March, 2007 |
CanBas and Takeda to Sign the Collaboration Agreement for Investigational Compounds for Treatment of Cancer. |
| October, 2007 |
Phase 1 clinical study of CBP501 (combination use with Cisplatin ) was initiated in US. |
| April, 2007 |
Patent approval for CBS2400 series(US). |
| February, 2006 |
Patent approval for CBP501(US). |
| May, 2006 |
Phase 1 clinical study of CBP501 (monotherapy) was initiated in US. |
| April, 2005 |
Patent for the screening method of the cell cycle G2 checkpoint issued by USPTO. |
| June, 2005 |
Patent application for low molecular compound CBS2400 series |
| Jan, 2003 |
Patent application for CBP501, candidate compound of anticancer drug that optimized TAT-S216. |
| January, 2003 |
1st Scientific Advisory Board (SAB) meeting. |
| September, 2002 |
US patent/PCT application for drug screening method, original peptide TAT-S216. |
| January, 2000 |
Founded in Toyota, Aichi Pref, for the purpose of research and development of new anticancer drug. |
